Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| RV-CL-MM-PI-004078 | Other Grant/Funding Number | Celgene Corporation |
Not provided
Not provided
low enrollment
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Celgene Corporation | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®), in multiple myeloma patients who are newly diagnosed and require treatment when compared to patients who receive lenalidomide and dexamethasone alone.
This research study is for men and women with newly diagnosed, previously untreated multiple myeloma. The purpose of this study is to observe the how well the different combinations of study drugs work as therapy for patients with newly diagnosed, transplant ineligible, previously untreated multiple myeloma.
The study will be done in two arms:
BiRd Arm:
Rd Arm:
Subjects will be treated in 28-day cycles and may continue treatment as long as they are responding to therapy and not experiencing unacceptable side effects or disease progression. There will be an evaluation at the end of each cycle. Participants will be in the study until disease progression or unacceptable toxicity.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BiRD treatment regimen | Experimental | Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles. |
|
| Rd treatment regimen | Active Comparator | Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Clarithromycin | Drug | 500mg PO twice daily on days 1-28 for a 28-day cycle. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Survival Duration Without Disease Progression | Calculate rate of progression-free survival for subjects following treatment BiRd regimen compared to Rd treatment regimen. Progression is determined by the International Myeloma Working Group Criteria. | Until disease progression or death from any cause, for a maximum of approximately 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Response Rate | Capture the number of subjects who demonstrate a complete or partial response to treatment with BiRD regimen, as compared to Rd. Complete and partial responses are defined by the International Myeloma Working Group Criteria. | 2 years |
| Number of Adverse Events Experienced |
Not provided
Inclusion Criteria:
Subject must voluntarily sign and understand written informed consent.
Subject is at least 65 years old at the time of signing the consent form.
Subject has histologically confirmed multiple myeloma that has never before been treated
Subject has no prior anti-myeloma treatment therapy within 14 days prior to initiation of study treatment except for corticosteroids with a maximum allowed dosage equivalent to three pulses of dexamethasone (40mg daily for 4 days equals one pulse). Patients may have received prior adjuvant antiresorptive therapy (i.e., pamidronate or zoledronic acid) as routine care, or radiation therapy as palliation for pain and/or spinal cord compression.
Subject has measurable disease as defined by > 0.5 g/dL serum monoclonal protein, >10 mg/dL involved serum free light chain (either kappa or lambda) provided that the serum free light chain ratio is abnormal, >0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s) of at least 1cm in greatest dimension as measured by either CT scanning or MRI.
Subject has a Karnofsky performance status ≥60% (>50% if due to bony involvement of myeloma (see Appendix IV).
Subject is able to take prophylactic anticoagulation as detailed in section 9.1 (patients intolerant to aspirin may use warfarin or low molecular weight heparin).
Subject is registered into the mandatory RevAssist® program, and is willing and able to comply with the requirements of RevAssist® program.
If subject is a female of childbearing potential (FCBP),†she must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing lenalidomide
Subject has a life expectancy ≥ 3 months
Subjects must meet the following laboratory parameters:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jorge Monge, MD | Weill Medical College of Cornell University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Colorado - Anschutz Cancer Center | Aurora | Colorado | 80045 | United States | ||
| Weill Cornell Medical College |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | BiRD Treatment Regimen | Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles. Clarithromycin: 500mg PO twice daily on days 1-28 for a 28-day cycle. Lenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle Dexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger. |
| FG001 | Rd Treatment Regimen | Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles. Lenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle Dexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | BiRD Treatment Regimen | Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles. Clarithromycin: 500mg PO twice daily on days 1-28 for a 28-day cycle. Lenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle Dexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Survival Duration Without Disease Progression | Calculate rate of progression-free survival for subjects following treatment BiRd regimen compared to Rd treatment regimen. Progression is determined by the International Myeloma Working Group Criteria. | Posted | Median | 95% Confidence Interval | days | Until disease progression or death from any cause, for a maximum of approximately 5 years |
|
Adverse events were collected from the time of informed consent until participants were removed from the study, or for a maximum of 60 months. Participants were removed at the time of disease progression, death, or study termination, whichever occurred first. This study was terminated early due to low accrual.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | BiRD Treatment Regimen | Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles. Clarithromycin: 500mg PO twice daily on days 1-28 for a 28-day cycle. Lenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle Dexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cellulitis | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | CTCAE (4.0) | Non-systematic Assessment |
The significance of these results is limited by the study's low accrual. The study's low accrual was due in part to the COVID-19 pandemic.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Multiple Myeloma Program Manager | Weill Cornell Medicine | 646.962.9376 | hyk4001@med.cornell.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jun 22, 2021 | Mar 23, 2023 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D017291 | Clarithromycin |
| D000077269 | Lenalidomide |
| D003907 | Dexamethasone |
| D002123 | Calcium Dobesilate |
| ID | Term |
|---|---|
| D004917 | Erythromycin |
| D018942 | Macrolides |
| D061065 | Polyketides |
| D007783 | Lactones |
| D009930 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Lenalidomide | Drug | 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle |
|
|
| Dexamethasone | Drug | 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger. |
|
|
Capture the number of adverse events experienced with BiRd regimen as compared to Rd regimen |
| 2 years |
| Overall Survival | Survival following treatment to the date of death of subjects on BiRd regimen as compared to Rd. | 4 years |
| Number of Days After Initiating Treatment With BiRd Regimen to Disease Progression, as Compared to Subjects on Rd Treatment Regimen. | Progression is determined by the International Myeloma Working Group Criteria. | Until disease progression for a maximum of approximately 5 years |
| Number of Patients With Objective Response Rate (CR+PR) | up to 3 years |
| Number of Patients With Complete Response Rate (CR) | Complete response is defined by the International Myeloma Working Group Criteria. | up to 3 years |
| Number of Days for Event-Free Survival | Descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms | approximately 5 years |
| Number of Days for Duration of Response | Descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms | up to 3 years |
| Number of Months to Progression-Free Survival 2 | Time from study entry until 2nd instance of disease progression. Progression is determined by the International Myeloma Working Group Criteria. Descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms. | approximately 5 years |
| Functional Assessment of Chronic Illness Therapy - Fatigue Subscale (FS; Version 4) Score of Patients Receiving BiRd vs Rd Treatment | The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) is a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function. The FACIT- Fatigue Subscore (FS) is comprised of 13 items, within the total 40-item FACIT-F, that assess fatigue and its impact. This analysis is only based on the FS score. Items are scored on a 5 point Likert-type scale. Item scores can range from 0 ("not at all") to 4 ("very much"), and the total, summed score from 0 to 52; lower scores indicate greater fatigue. The recall period for each item is the past 7 days. Data is descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms. | up to 3 years |
| New York |
| New York |
| 10065 |
| United States |
| BG001 | Rd Treatment Regimen | Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles. Lenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle Dexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger. |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles. Lenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle Dexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger. |
|
|
| Secondary | Overall Response Rate | Capture the number of subjects who demonstrate a complete or partial response to treatment with BiRD regimen, as compared to Rd. Complete and partial responses are defined by the International Myeloma Working Group Criteria. | Posted | Count of Participants | Participants | 2 years |
|
|
|
| Secondary | Number of Adverse Events Experienced | Capture the number of adverse events experienced with BiRd regimen as compared to Rd regimen | Posted | Number | adverse events | 2 years |
|
|
|
| Secondary | Overall Survival | Survival following treatment to the date of death of subjects on BiRd regimen as compared to Rd. | Posted | Median | 95% Confidence Interval | days | 4 years |
|
|
|
| Secondary | Number of Days After Initiating Treatment With BiRd Regimen to Disease Progression, as Compared to Subjects on Rd Treatment Regimen. | Progression is determined by the International Myeloma Working Group Criteria. | Posted | Median | 95% Confidence Interval | days | Until disease progression for a maximum of approximately 5 years |
|
|
|
| Secondary | Number of Patients With Objective Response Rate (CR+PR) | Posted | Count of Participants | Participants | up to 3 years |
|
|
|
| Secondary | Number of Patients With Complete Response Rate (CR) | Complete response is defined by the International Myeloma Working Group Criteria. | Posted | Count of Participants | Participants | up to 3 years |
|
|
|
| Secondary | Number of Days for Event-Free Survival | Descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms | Posted | Median | 95% Confidence Interval | days | approximately 5 years |
|
|
|
| Secondary | Number of Days for Duration of Response | Descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms | Posted | Median | 95% Confidence Interval | days | up to 3 years |
|
|
|
| Secondary | Number of Months to Progression-Free Survival 2 | Time from study entry until 2nd instance of disease progression. Progression is determined by the International Myeloma Working Group Criteria. Descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms. | Data not collected due to early trial termination due to low accrual. | Posted | approximately 5 years |
|
|
| Secondary | Functional Assessment of Chronic Illness Therapy - Fatigue Subscale (FS; Version 4) Score of Patients Receiving BiRd vs Rd Treatment | The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) is a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function. The FACIT- Fatigue Subscore (FS) is comprised of 13 items, within the total 40-item FACIT-F, that assess fatigue and its impact. This analysis is only based on the FS score. Items are scored on a 5 point Likert-type scale. Item scores can range from 0 ("not at all") to 4 ("very much"), and the total, summed score from 0 to 52; lower scores indicate greater fatigue. The recall period for each item is the past 7 days. Data is descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms. | Posted | Mean | Full Range | Score on a scale | up to 3 years |
|
|
|
| 2 |
| 7 |
| 6 |
| 7 |
| 7 |
| 7 |
| EG001 | Rd Treatment Regimen | Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles. Lenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle Dexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger. | 4 | 5 | 3 | 5 | 5 | 5 |
| Allergic Reaction | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Urinary Tract Infection | Renal and urinary disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Fall | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Acute Hypoxic Respiratory Failure | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Syncope | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Secondary Primary Malignancy | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | CTCAE (4.0) | Non-systematic Assessment |
|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Acute Kidney Injury | Renal and urinary disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Atrial Fibrillation | Cardiac disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Edema Limbs | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Skin Infection | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| COVID-19 Infection | Infections and infestations | CTCAE (4.0) | Non-systematic Assessment |
|
| Neutropenia | Blood and lymphatic system disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Hyponatremia | Investigations | CTCAE (4.0) | Non-systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Agitation | Psychiatric disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Decreased albumin | Investigations | CTCAE (4.0) | Non-systematic Assessment |
|
| Increased alkaline phosphatase | Investigations | CTCAE (4.0) | Non-systematic Assessment |
|
| Anorexia | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| anxiety | Psychiatric disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Cataract | Eye disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Cold Symptoms | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Dry Skin | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Fall | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Fatigue | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Hair loss | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Headache | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Hypertension | Investigations | CTCAE (4.0) | Non-systematic Assessment |
|
| Hypocalcemia | Investigations | CTCAE (4.0) | Non-systematic Assessment |
|
| Hypokalemia | Investigations | CTCAE (4.0) | Non-systematic Assessment |
|
| Hypomagnesemia | Investigations | CTCAE (4.0) | Non-systematic Assessment |
|
| Insomnia | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Dizziness | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Dysgeusia | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Leukocytosis | Investigations | CTCAE (4.0) | Non-systematic Assessment |
|
| Leukopenia | Investigations | CTCAE (4.0) | Non-systematic Assessment |
|
| Edema Limbs | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Pain | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Lymphopenia | Investigations | CTCAE (4.0) | Non-systematic Assessment |
|
| Maculo-papular rash | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Nausea | Gastrointestinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Peripheral Neuropathy | Nervous system disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Post-nasal drip | Respiratory, thoracic and mediastinal disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Skin Atrophy | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Skin Hyperpigmentation | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Tachycardia | Cardiac disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Thrombocytopenia | Investigations | CTCAE (4.0) | Non-systematic Assessment |
|
| Urinary Retention | Renal and urinary disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Urinary Tract Infection | Renal and urinary disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Vaginal Yeast Infection | Reproductive system and breast disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Weight Loss | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Skin Ulceration | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Allergic Rhinitis | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Body Aches | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Bruising | Blood and lymphatic system disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Dehydration | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Depression | Psychiatric disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Generalized muscle weakness | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Gun sensitivity/inflammation | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Extremity Cramps | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Lower extremity weakness | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Lung Infection | Infections and infestations | CTCAE (4.0) | Non-systematic Assessment |
|
| Malaise | General disorders | CTCAE (4.0) | Non-systematic Assessment |
|
| Mucosal Infection/Thrush | Infections and infestations | CTCAE (4.0) | Non-systematic Assessment |
|
| Muscle spasm | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Non-systematic Assessment |
|
Not provided
Not provided
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| Organic Chemicals |
| D010797 | Phthalimides |
| D010795 | Phthalic Acids |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D010881 | Piperidones |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D054833 | Isoindoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |
| D001557 | Benzenesulfonates |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D001190 | Arylsulfonates |
| D017739 | Arylsulfonic Acids |
| D013451 | Sulfonic Acids |
| D013456 | Sulfur Acids |
| D013457 | Sulfur Compounds |